Literature DB >> 9873805

Prions and haemophilia: assessment of risk.

B L Evatt1.   

Abstract

Based on information accumulated to date, it is still difficult to assess the risk of Creutzfeldt-Jakob disease (CJD) and blood transfusion with any degree of confidence. However, it is reasonable to conclude that CJD is produced by a transmittable agent which is probably contained in low titer in the blood of infected people and animals. From the present clinical and epidemiological studies, transmission by blood or blood products appears to be a rare or non-existent cause of current and past cases of CJD in humans. Since blood products are necessary to prevent the immediate risk of death or significant morbidity in many clinical conditions, therapeutic decisions should be made after consideration of the known risk in these situations vs the theoretical long-term risk of the rare occurrence of CJD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9873805     DOI: 10.1046/j.1365-2516.1998.440628.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  3 in total

1.  Stable Expression of Recombinant Factor VIII in CHO Cells Using Methotrexate-Driven Transgene Amplification.

Authors:  N A Orlova; S V Kovnir; I I Vorobiev; A S Yuriev; A G Gabibov; A I Vorobiev
Journal:  Acta Naturae       Date:  2012-01       Impact factor: 1.845

Review 2.  Prevention and Management of Bleeding Episodes in Children with Hemophilia.

Authors:  Rolf C R Ljung
Journal:  Paediatr Drugs       Date:  2018-10       Impact factor: 3.022

3.  Blood Clotting Factor VIII: From Evolution to Therapy.

Authors:  N A Orlova; S V Kovnir; I I Vorobiev; A G Gabibov; A I Vorobiev
Journal:  Acta Naturae       Date:  2013-04       Impact factor: 1.845

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.